Arcutis Biotherapeutics Financial Statements (ARQT)
|
|
|
|
Report date
|
|
|
22.02.2022 |
28.02.2023 |
27.02.2024 |
25.02.2025 |
25.02.2026 |
|
06.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
3.69 |
59.6 |
196.5 |
376.1 |
|
415.6 |
|
Operating Income, bln rub |
|
|
-206.5 |
-301.6 |
-241.1 |
-128.4 |
-12.2 |
|
3.21 |
|
EBITDA, bln rub |
? |
|
-205.6 |
-294.6 |
-227.4 |
-109.6 |
2.48 |
|
12.8 |
|
Net profit, bln rub |
? |
|
-206.4 |
-311.5 |
-262.1 |
-140.0 |
-16.1 |
|
-2.38 |
|
|
OCF, bln rub |
? |
|
-174.6 |
-257.7 |
-247.1 |
-112.2 |
-5.63 |
|
27.0 |
|
CAPEX, bln rub |
? |
|
0.995 |
23.3 |
0.428 |
0.143 |
0.686 |
|
0.078 |
|
FCF, bln rub |
? |
|
-175.6 |
-281.0 |
-247.5 |
-112.3 |
-6.31 |
|
26.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
205.8 |
304.6 |
295.7 |
305.8 |
351.6 |
|
374.8 |
|
Cost of production, bln rub |
|
|
0.763 |
0.754 |
4.99 |
19.1 |
36.7 |
|
37.6 |
|
R&D, bln rub |
|
|
145.6 |
182.4 |
110.6 |
76.4 |
77.1 |
|
90.1 |
|
Interest expenses, bln rub |
|
|
0.000 |
15.7 |
29.7 |
27.2 |
12.1 |
|
13.5 |
|
|
Assets, bln rub |
|
|
408.2 |
449.3 |
341.4 |
348.9 |
433.0 |
|
460.0 |
|
Net Assets, bln rub |
? |
|
297.7 |
209.6 |
88.7 |
157.5 |
189.5 |
|
189.6 |
|
Debt, bln rub |
|
|
77.6 |
202.5 |
205.9 |
110.6 |
6.27 |
|
13.2 |
|
Cash, bln rub |
|
|
388.6 |
409.6 |
271.9 |
228.0 |
221.0 |
|
224.0 |
|
Net debt, bln rub |
|
|
-311.0 |
-207.0 |
-65.9 |
-117.4 |
-214.7 |
|
-210.8 |
|
|
Ordinary share price, rub |
|
|
20.7 |
|
|
13.9 |
29.0 |
|
23.6 |
|
Number of ordinary shares, mln |
|
|
49.4 |
55.0 |
69.3 |
121.0 |
127.2 |
|
129.4 |
|
|
Market cap, bln rub |
|
|
1 025 |
0 |
0 |
1 685 |
3 695 |
|
3 048 |
|
EV, bln rub |
? |
|
714 |
-207 |
-66 |
1 568 |
3 480 |
|
2 837 |
|
Book value, bln rub |
|
|
298 |
202 |
82 |
148 |
175 |
|
175 |
|
|
EPS, rub |
? |
|
-4.18 |
-5.66 |
-3.78 |
-1.16 |
-0.13 |
|
-0.02 |
|
FCF/share, rub |
|
|
-3.55 |
-5.11 |
-3.57 |
-0.93 |
-0.05 |
|
0.21 |
|
BV/share, rub |
|
|
6.03 |
3.68 |
1.19 |
1.22 |
1.37 |
|
1.36 |
|
|
EBITDA margin, % |
? |
|
|
-7 991% |
-381.6% |
-55.8% |
0.66% |
|
3.07% |
|
Net margin, % |
? |
|
|
-8 450% |
-439.8% |
-71.3% |
-4.29% |
|
-0.57% |
|
FCF yield, % |
? |
|
-17.1% |
|
|
-6.66% |
-0.17% |
|
0.88% |
|
ROE, % |
? |
|
-69.3% |
-148.6% |
-295.6% |
-88.9% |
-8.52% |
|
-1.25% |
|
ROA, % |
? |
|
-50.6% |
-69.3% |
-76.8% |
-40.1% |
-3.73% |
|
-0.52% |
|
|
P/E |
? |
|
-4.97 |
0.00 |
0.00 |
-12.0 |
-228.9 |
|
-1 283 |
|
P/FCF |
|
|
-5.83 |
0.00 |
0.00 |
-15.0 |
-585.5 |
|
113.2 |
|
P/S |
? |
|
|
0.00 |
0.00 |
8.57 |
9.82 |
|
7.33 |
|
P/BV |
? |
|
3.44 |
0.00 |
0.00 |
11.4 |
21.2 |
|
17.4 |
|
EV/EBITDA |
? |
|
-3.47 |
0.70 |
0.29 |
-14.3 |
1 403 |
|
222.1 |
|
Debt/EBITDA |
|
|
1.51 |
0.70 |
0.29 |
1.07 |
-86.6 |
|
-16.5 |
|
|
R&D/CAPEX, % |
|
|
14 629% |
783.6% |
25 835% |
53 441% |
11 232% |
|
115 558% |
|
|
CAPEX/Revenue, % |
|
|
|
631.7% |
0.72% |
0.07% |
0.18% |
|
0.02% |
|
| Arcutis Biotherapeutics shareholders |
